According to all these considerations, it could be hypothesized that, in order to optimise the relevance of FVIIa–AT as an indirect marker of TF activity, the sampling time for plasma assays should be after a night of fasting (to avoid the potential interference of fat-containing meals) in clinically stable subjects (without any acute thrombotic events), not taking drugs reducing FVII levels (like VKAs) or with concomitant medical condition reducing FVII and FVIIa–AT levels (like advanced liver disease or disseminated intravascular coagulation). This evidence concerns the gene TF and Disseminated intravascular coagulation.